Publications by authors named "K J Blackmore"
Background: A prospective cohort study was undertaken within the PERSPECTIVE I&I project to evaluate healthcare resource utilization and costs associated with breast cancer risk assessment and screening and overall costs stratified by risk level, in Ontario, Canada.
Methods: From July 2019 to December 2022, 1997 females aged 50 to 70 years consented to risk assessment and received their breast cancer risk level and personalized screening action plan in Ontario. The mean costs for risk-stratified screening-related activities included risk assessment, screening and diagnostic costs.
Risk-stratified breast screening has been proposed as a strategy to overcome the limitations of age-based screening. A prospective cohort study was undertaken within the PERSPECTIVE I&I project, which will generate the first Canadian evidence on multifactorial breast cancer risk assessment in the population setting to inform the implementation of risk-stratified screening. Recruited females aged 40-69 unaffected by breast cancer, with a previous mammogram, underwent multifactorial breast cancer risk assessment.
View Article and Find Full Text PDFArticle Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is a medical condition affecting 1 in 3 adults and can lead to serious health problems.
- Researchers studied how a specific part of the brain affects this condition in mice by activating and blocking certain brain cells.
- The study found that changing brain signals can help prevent or reduce NAFLD, suggesting new ways to treat this disease in people.
Article Synopsis
- A study analyzed healthcare costs and resource use for nearly 645,000 women aged 50-74 in the Ontario Breast Screening Program between 2011-2014, looking at different screening frequencies and outcomes.
- Results showed that women aged 60-74 incurred the highest average costs, particularly with annual screenings linked to family or personal history, totaling CAD 5425.
- Although annual screenings for women with dense breasts led to higher costs per breast cancer diagnosis, they also had lower costs per false positive compared to biennial screenings, indicating a need for careful resource allocation in breast cancer screening programs.